Novartis, Dynavax to develop "universal" flu shots

07/24/2008 | American City Business Journals

Novartis Vaccines and Diagnostics agreed to supply its trivalent influenza vaccine that will be used in developing Dynavax Technologies' experimental "universal" flu vaccine. In return, Novartis gains the exclusive option to discuss development and marketing deals with Dynavax. Financial terms of the partnership were not disclosed.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX